Loading organizations...
OneHealth Haihe Capital operates as an investment firm, deploying capital across the healthcare and biotechnology sectors. The firm empowers innovative companies developing novel therapeutic solutions, medical technologies, and specialized healthcare services. Its core approach provides growth-stage funding, accelerating promising life science advancements to market.
Established with insight into the capital needs of the evolving biopharmaceutical and medical innovation landscape, this investment entity aims to translate scientific discoveries into accessible healthcare through targeted financial support. It focuses on drug discovery, medical devices, and digital health, bridging research and commercialization.
The firm's portfolio companies utilize its investment to advance pipelines and expand capabilities. OneHealth Haihe Capital collaborates with these ventures, enabling them to bring innovations to patients and providers. Its vision fosters a robust health technology ecosystem, driving improvements in patient outcomes and advancing global medical practices.
Key people at OneHealth Haihe Capital.
OneHealth Haihe Capital has 1 tracked investment across 1 company. The latest tracked deal is $42.1M Series B in iRegene Therapeutics in September 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 9, 2025 | iRegene Therapeutics | $42.1M Series B | Chuangjing Capital, Northern Light Venture Capital, Onehealth Haihe Capital | — |
Key people at OneHealth Haihe Capital.